Adults with adequate organ function and either immunotherapy-naïve (parts 1c/1e) or anti–PD-(L)1 relapsed or refractory (part 2A) melanoma were enrolled and received cobolimab 100, 300, or 900 mg and dostarlimab 500 mg every 3 weeks. This evidence concerns the gene CD274 and melanoma.